Skip to main content
. 2015 Aug 28;3:71. doi: 10.3389/fped.2015.00071

Figure 1.

Figure 1

Flow-associated PAH and effects of EPO treatment. Flow-associated PAH and effects of EPO treatment on (A) wall thickness of intra-acinar pulmonary vessels, (B) right ventricular hypertrophy [RV/(LV + IVS)], and (C) systolic pulmonary arterial pressure. (D) Examples of pulmonary histopathology (Verhoeff-staining) of intra-acinar pulmonary vessels. CON, control group, n = 12; PAH, untreated pulmonary arterial hypertension, n = 12–14; PAH + EPO, PAH treated with erythropoietin (EPO), n = 12–15. Differences between the PAH and CON groups were analyzed using t-tests for normally distributed data and Mann–Whitney U testing for not normally distributed data. Differences between the untreated and treated PAH groups (groups 1–4) were tested by one-way ANOVA followed by Fisher’s protected LSD post hoc testing (hematocrit, hemodynamics, RV hypertrophy, pulmonary vascular remodeling). *p < 0.05 vs. CON, #p < 0.05 vs. PAH.